Switch theme
Sign up to access all valuation multiples
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company’s product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
2017
110
Last FY Revenue n/a
LTM EBITDA -$172M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Edgewise Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$172M.
In the most recent fiscal year, Edgewise Therapeutics achieved revenue of n/a and an EBITDA of -$157M.
Edgewise Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Edgewise Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$172M | XXX | -$157M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$174M | XXX | -$159M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$152M | XXX | -$134M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Edgewise Therapeutics's stock price is $14.
Edgewise Therapeutics has current market cap of $1.5B, and EV of $1.1B.
See Edgewise Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $1.5B | XXX | XXX | XXX | XXX | $-1.57 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Edgewise Therapeutics has market cap of $1.5B and EV of $1.1B.
Edgewise Therapeutics's trades at n/a EV/Revenue multiple, and -6.8x EV/EBITDA.
Equity research analysts estimate Edgewise Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Edgewise Therapeutics has a P/E ratio of -9.9x.
See valuation multiples for Edgewise Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.2x | XXX | -6.8x | XXX | XXX | XXX |
| EV/EBIT | -6.1x | XXX | -6.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -9.9x | XXX | -11.2x | XXX | XXX | XXX |
| EV/FCF | -8.7x | XXX | -9.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEdgewise Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Edgewise Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Edgewise Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Edgewise Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Edgewise Therapeutics acquired XXX companies to date.
Last acquisition by Edgewise Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Edgewise Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Edgewise Therapeutics founded? | Edgewise Therapeutics was founded in 2017. |
| Where is Edgewise Therapeutics headquartered? | Edgewise Therapeutics is headquartered in United States of America. |
| How many employees does Edgewise Therapeutics have? | As of today, Edgewise Therapeutics has 110 employees. |
| Who is the CEO of Edgewise Therapeutics? | Edgewise Therapeutics's CEO is Dr. Kevin Koch, PhD. |
| Is Edgewise Therapeutics publicy listed? | Yes, Edgewise Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Edgewise Therapeutics? | Edgewise Therapeutics trades under EWTX ticker. |
| When did Edgewise Therapeutics go public? | Edgewise Therapeutics went public in 2021. |
| Who are competitors of Edgewise Therapeutics? | Similar companies to Edgewise Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Edgewise Therapeutics? | Edgewise Therapeutics's current market cap is $1.5B |
| Is Edgewise Therapeutics profitable? | Yes, Edgewise Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Edgewise Therapeutics? | Edgewise Therapeutics's last 12 months EBITDA is -$172M. |
| What is the current EV/EBITDA multiple of Edgewise Therapeutics? | Current EBITDA multiple of Edgewise Therapeutics is -6.2x. |
| What is the current FCF of Edgewise Therapeutics? | Edgewise Therapeutics's last 12 months FCF is -$123M. |
| What is the current EV/FCF multiple of Edgewise Therapeutics? | Current FCF multiple of Edgewise Therapeutics is -8.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
